Get the Stockscreener App
4.75
1.25%
-0.06
Pre-market:
4.75
Unicycive Therapeutics Inc stock is traded at $4.75, with a volume of 423.00K.
It is down -1.25% in the last 24 hours and up +8.94% over the past month.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
See More
Previous Close:
$4.81
Open:
$4.82
24h Volume:
423.00K
Relative Volume:
0.93
Market Cap:
$83.89M
Revenue:
-
Net Income/Loss:
$-30.54M
P/E Ratio:
-3.0645
EPS:
-1.55
Net Cash Flow:
$-18.30M
1W Performance:
-7.41%
1M Performance:
+8.94%
6M Performance:
+628.97%
1Y Performance:
+787.85%
1-Day Range:
$4.63
$4.83
1-Week Range:
$4.62
$5.40
52-Week Range:
$0.4139
$8.2457
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Name
Unicycive Therapeutics Inc
Sector
Industry
Phone
650-384-0642
Address
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Compare UNCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
4.75 | 84.95M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | Guggenheim | Buy |
| Apr-04-24 | Initiated | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Stock (UNCY) Latest News
Unicycive Therapeutics to Participate in a Fireside Chat at - GlobeNewswire
Sentiment analysis tools applied to Unicycive Therapeutics Inc.2025 Market Trends & Verified Entry Point Signals - newser.com
What moving averages say about Unicycive Therapeutics Inc.July 2025 Earnings & Safe Capital Growth Tips - newser.com
Live market analysis of Unicycive Therapeutics Inc.Entry Point & Expert Curated Trade Setup Alerts - newser.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect - ACCESS Newswire
Will Unicycive Therapeutics Inc. stock beat EPS estimatesJuly 2025 EndofMonth & Weekly Setup with High ROI Potential - newser.com
Why Unicycive Therapeutics Inc. stock remains resilientWeekly Risk Report & Advanced Swing Trade Entry Plans - newser.com
Does Unicycive Therapeutics Inc. show high probability of reboundJuly 2025 Sector Moves & Reliable Breakout Forecasts - newser.com
Identifying reversal signals in Unicycive Therapeutics Inc.2025 Geopolitical Influence & Consistent Profit Trade Alerts - newser.com
Unicycive Therapeutics (NASDAQ:UNCY) Raised to Hold at Wall Street Zen - MarketBeat
HC Wainwright Analysts Increase Earnings Estimates for UNCY - MarketBeat
Unicycive Leaders Sued for Touting Kidney Treatment’s Prospects - Bloomberg Law News
Unicycive Therapeutics (NASDAQ:UNCY) Receives Sell (E+) Rating from Weiss Ratings - MarketBeat
UNICYCIVE ALERT: Bragar Eagel & Squire, P.C. is Investigating Unicycive Therapeutics, Inc. ... - Bluefield Daily Telegraph
UNICYCIVE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Is Unicycive Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Big Picture & High Accuracy Trade Signal Alerts - newser.com
Can Unicycive Therapeutics Inc. stock hit analyst price targets2025 Top Decliners & Reliable Entry Point Alerts - newser.com
Custom strategy builders for tracking Unicycive Therapeutics Inc.Trade Entry Report & Long-Term Investment Growth Plans - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), United Therapeutics (UTHR) and Unicycive Therapeutics (UNCY) - The Globe and Mail
How Unicycive Therapeutics Inc. stock performs in interest rate cyclesJuly 2025 Short Interest & AI Powered Buy/Sell Recommendations - newser.com
Optimistic Buy Rating for Unicycive Therapeutics Driven by Promising Clinical Progress and Financial Stability - TipRanks
Analyzing net buyer seller activity in Unicycive Therapeutics Inc.2025 Geopolitical Influence & Growth Focused Entry Reports - newser.com
Will a bounce in Unicycive Therapeutics Inc. offer an exit2025 Price Action Summary & Step-by-Step Swing Trade Plans - newser.com
Guggenheim Sticks to Its Buy Rating for Unicycive Therapeutics (UNCY) - The Globe and Mail
Benchmark Co. Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Connect - ACCESS Newswire
Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference - The Manila Times
Unicycive Therapeutics to Present New Data for Oxylanthanum Carbonate at ASN Kidney Week 2025 - Quiver Quantitative
Unicycive (NASDAQ: UNCY) to present OLC data: 7x lower pill volume, 2x fewer pills at ASN - Stock Titan
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alkermes (ALKS), Arcutis Biotherapeutics (ARQT) and Unicycive Therapeutics (UNCY) - The Globe and Mail
HC Wainwright & Co. Maintains Unicycive Therapeutics (UNCY) Buy Recommendation - Nasdaq
Unicycive Therapeutics price target raised to $22 from $9 at H.C. Wainwright - TipRanks
Is Unicycive Therapeutics Inc. stock attractive for growth ETFs2025 Buyback Activity & Fast Momentum Stock Entry Tips - fcp.pa.gov.br
Can Unicycive Therapeutics Inc. stock rebound after recent weaknessJuly 2025 Decliners & AI Powered Buy/Sell Recommendations - Fundação Cultural do Pará
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Unicycive provides update on meeting with FDA, resubmission of NDA for OLC - TipRanks
Unicycive Therapeutics Plans To Resubmit NDA For Oxylanthanum Carbonate - Nasdaq
Unicycive Therapeutics Updates FDA Application for OLC - TipRanks
Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End - The Manila Times
Unicycive Therapeutics Provides Update on FDA Meeting and NDA Resubmission Timeline for Oxylanthanum Carbonate - Quiver Quantitative
Unicycive Therapeutics Provides Update From FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End - 富途牛牛
Should you hold or exit Unicycive Therapeutics Inc. nowMarket Activity Summary & Daily Stock Momentum Reports - newser.com
Aug Sentiment: Is Unicycive Therapeutics Inc. stock oversold or undervaluedJuly 2025 Analyst Calls & Real-Time Volume Analysis Alerts - fcp.pa.gov.br
Unicycive Therapeutics Inc Stock (UNCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):